BCMA / Luciferase - CHO Recombinant Cell Line
Catalog #
79724
$9,780
*
●
●
Purchase
Description
Recombinant CHO-K1 cells constitutively expressing both the human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192) and the firefly luciferase reporter. Surface expression of BCMA was confirmed by flow cytometry.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
●
Synonyms
TNFRSF17, BCM, BCMA, CD269, TNFRSF13A, tumor necrosis factor receptor superfamily member 17
●
Product Data Gallery
Product Info
Storage and Usage
Citations
Host Cell Line
CHO K1. Chinese Hamster Ovary.
Supplied As
Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Materials Required But Not Supplied
• Thaw Medium 3 (BPS Bioscience, #60186)
• Growth Medium 3A (BPS Bioscience, #60188)
• 96-well tissue culture-treated white clear-bottom assay plate
• ONE-Step luciferase assay system (BPS Bioscience, #60690) or other luciferase
reagent for measuring firefly luciferase activity
• Luminometer
UniProt #
Q02223
Mycoplasma Testing
This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza,
#LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set
(Lonza, #LT07-518) was used as a positive control.
Background
B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.